Bristol-Myers Squibb Suspends Development of Experimental Hepatitis C Drug

by Kathy Jones on  August 24, 2012 at 7:36 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

American pharmaceutical giant Bristol-Myers Squibb has announced the immediate suspension of the development of its experimental hepatitis C drug that was aimed at treating liver disease following the death of one patient while eight more had to be hospitalized.
 Bristol-Myers Squibb Suspends Development of Experimental Hepatitis C Drug
Bristol-Myers Squibb Suspends Development of Experimental Hepatitis C Drug

The company was conducting Phase II trials for the effectiveness of the drug, known as BMS-986094, which it had acquired following a $2.5 billion acquisition of Inhibitex Inc.

The trial was halted on August 1 following the death of a patient due to heart failure while a follow up on other patients led to the hospitalization of eight more. BMS-986094 belongs to a new class of drugs known as nucleotide polymerase inhibitors.

Bristol added that it is working closely with the US Food and Drug Administration to follow up on the remaining patients with its chief scientific officer, Elliott Sigal stating, "We will also work expeditiously to share the results of our further investigations more broadly in the medical and scientific community."

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Hepatitis A Hepatitis B Vasculitis Signature Drug Toxicity Silent Killer Diseases Liver Aplastic Anemia Hepatitis C Hepatitis 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...